PROCEPT BioRobotics Faces Securities Class Action Suit

SAN FRANCISCO, Sept. 19, 2026 /CourierPR/ -- Investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) who purchased common stock between February 28, 2024, and February 25, 2026, are urged to take action. A securities class action has been filed against the company, alleging that it misled investors about the performance of its single-use handpiece sales, a key component of its proprietary Aquablation therapy.

According to the lawsuit, PROCEPT and its executives violated federal securities laws by failing to disclose crucial information about the company's business and financial condition. Specifically, the lawsuit claims that the company engaged in an extensive discount program to incentivize customers to place bulk orders, which artificially inflated reported unit sales and revenues. This program, which was previously undisclosed, was designed to drive sales in the final weeks of each quarter, potentially at the expense of future periods.

The allegations stem from a series of events that began with the company's Q2 2025 financial results, announced on August 6, 2025. PROCEPT reported that its handpiece sales had unexpectedly deteriorated, missing consensus estimates by a wide margin. This was followed by the company's Q3 2025 results, which again missed expected handpiece unit sales. During the corresponding earnings call, management acknowledged that the company had not been managing customer inventory effectively, with some customers carrying too much excess inventory.

Finally, on February 25, 2026, PROCEPT announced its Q4 2025 results. For the first time, the company disclosed the actual number of procedures in the field and revealed that U.S. handpiece sales had materially exceeded procedures in each quarter since Q1 2023. This revelation indicated that cumulative excess customer inventory of handpieces was over 10,000 units, and U.S. handpiece sales had sequentially cratered by 30%. In response, the company announced the elimination of its bulk order discount program, which had been designed to incentivize customers to make large purchases during the final weeks of every quarter.

As a result of these events, the price of PROCEPT shares had steadily declined by $22.06, or over 48% from the close on August 6, 2025. National shareholders rights firm Hagens Berman Sobol Shapiro LLP is investigating the legal claims and encourages investors who suffered substantial losses to submit their losses now. Persons with knowledge who may be able to assist the investigation are invited to contact the firm’s attorneys.

Hagens Berman, a global plaintiffs' rights complex litigation firm, has a robust practice in corporate accountability. The firm has secured more than $2.9 billion in this area of law.

If you invested in PROCEPT and have substantial losses, or have knowledge that will assist the firm's investigation, submit your losses now.